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Introduction {#sec005}
============

Natural Killer (NK) cells are key effectors of innate immunity in response to virus-infected and transformed cells \[[@pone.0225151.ref001], [@pone.0225151.ref002]\]. NK cell functions are regulated by the balance of signal transduction through their activating and inhibitory receptors. Effector functions of NK cells include direct cytotoxic activity and cytokine release \[[@pone.0225151.ref003]\]. Killer Immunoglobulin-like receptors (KIRs) are highly polymorphic glycoproteins expressed on NK cells. Genetic diversity of *KIRs* includes variations in gene content and copy number as well as allelic polymorphisms \[[@pone.0225151.ref004]--[@pone.0225151.ref008]\]. *KIR* members include 15 functional genes (*2DL1-4*, *2DL5A*, *2DL5B*, *2DS1-5*, *3DL1-3* and *3DS1*), and 2 pseudogenes (*2DP1*, *3DP1*). KIR ligands are human leukocyte antigen (HLA)-class I molecules that are expressed in all nucleated cells. The interactions between KIR and HLA class I molecules regulate NK cell function. To date, impact of *KIR* diversity has been investigated in several human diseases and conditions that include infection, autoimmunity, inflammatory disorders, hematopoietic stem transplantation and reproduction \[[@pone.0225151.ref009]\]. Recent studies have shown that *KIR* polymorphisms are associated with susceptibility to Human Immunodeficiency Virus (HIV)-1 infection and HIV disease progression \[[@pone.0225151.ref010]--[@pone.0225151.ref012]\]. In addition, *3DL1/S1* locus is unusual in that it shows allelic polymorphisms encoding inhibitory (*3DL1*) or activating (*3DS1*) receptors \[[@pone.0225151.ref013], [@pone.0225151.ref014]\]. These *3DL1/S1* functions have been reported as protecting against HIV-infection and progression \[[@pone.0225151.ref015]--[@pone.0225151.ref018]\]. Moreover, increasing numbers of association studies of *3DL1/S1* and HIV acquisition have compared HIV-infected (HIVI) and HIV-exposed seronegative (HESN) individuals. HESN individuals are those who resist HIV-infection despite repeated exposure to the virus. HESN individuals were found to have enriched *3DL1/S1* genotypes \[[@pone.0225151.ref019]\]. The mechanism by which HESN individuals are naturally protected renders this group as more suitable than healthy controls \[[@pone.0225151.ref019], [@pone.0225151.ref020]\]. Therefore, the resistance of such individuals to HIV has been the focus of interest in identifying the mechanisms of natural protection. For HESN individuals with *3DS1* and/or *3DL1*, it has been proposed that both *KIR* polymorphisms are required for increased NK cell activity in the killing of HIV-infected cells \[[@pone.0225151.ref021]\]. However, not all studies agree with KIR's role in HIV infection \[[@pone.0225151.ref022]\], rendering inconsistency to the cumulative outcomes of the reported studies. Their conclusions may have been limited by inadequate statistical power because of small sample sizes and lack of proportional controls. Given these inconsistencies, we perform a meta-analysis to obtain better estimates of precision and statistical power to help establish associations of the *KIR* polymorphisms with HIV acquisition.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

Three databases (PubMed, Google Scholar and Science Direct) were searched for association studies as of November 28, 2018. The terms used were "*Killer Immunoglobulin-like Receptor*", '*KIR*", "*HIV*", "*Human Immunodeficiency Virus*", "*HESN*" "*HIV-exposed seronegative*" as medical subject headings and text, without language restrictions. References cited in the retrieved articles were screened manually to identify additional eligible studies.

Inclusion and exclusion criteria {#sec008}
--------------------------------

SC and NP independently decided on which articles were to be included. This was then discussed in order to reach an agreement; otherwise, NS adjudicated so that consensus was obtained. Inclusion criteria included the following: (1) articles evaluating associations between *KIR* polymorphisms and risk for HIV acquisition; (2) the studies have a case--control study design; (3) HIVI cases; (4) controls were HESN, tested with HIV enzyme immunoassay or reverse transcriptase-polymerase chain reaction for at least 18 months; (5) sufficient genotype or allele frequency data to allow calculation of odds ratios (ORs) and 95% confidence intervals (CIs). Excluded articles were those that: (1) evaluated associations between *KIR* polymorphisms and HIV progression; (2) had no controls or with healthy controls; (3) unconfirmed HIV infection; (4); were reviews; (5) had duplicate data; (6) had incomplete or absent genotype data.

Data extraction {#sec009}
---------------

Two investigators (SC and NP) independently extracted data and reached a consensus on all the items, adjudicated by a third investigator (NS). The following information was obtained from each publication: (i) first author's name; (ii) published year; (iii) country of origin; (iv) ethnicity; (v) total sample sizes; (vi) number of HIVI and HESN; (vi) genotyping platform; (vii) *KIR* gene content polymorphisms: (viii) *KIR3DL1/S1* genotypes and minor allele frequencies. In attempts to fill missing information, we contacted the primary-study authors. None of the included studies mentioned the influence of environment, nor were data provided.

Quality of the studies {#sec010}
----------------------

SC and NP assessed the methodological quality of the included studies. The Clark-Baudouin (CB) scale was used for this purpose \[[@pone.0225151.ref023]\] because it focuses on statistical (P-values, power and corrections for multiplicity) and genetic (genotyping methods) features of the included studies. CB scores range from 0 (worst) to 10 (best) where quality is rated as low (**\<** 5), moderate (5--6) and high (7--10).

Data synthesis {#sec011}
--------------

Risks of HIV acquisition (using raw data for frequencies) were estimated for each study wherein ORs were calculated for the 13 KIR genes (*2DL1-3*, *2DL5A*, *2DL5B*, *2DS1-3*, *2DS4D*, *2DS4F*, *2DS5*, *3DL1* and *3DS1*) and the *3DL1/S1* genotypes. The framework and pseudogenes were excluded for analysis (*2DL4*, *3DL2*, *3DL3*, *2DP1* and *3DP1*) because of their presence in all haplotypes. Gene content analysis (presence/absence) was based on the frequency data of HIVI and HESN. Use of HESN as controls precluded testing for Hardy-Weinberg Equilibrium. The combination of gene content variation and genotype distribution precluded the use of standard genetic modeling, but allowed application of the allele genotype model. Subgrouping was ethnicity-based (Asian, Caucasian and African). Heterogeneity between studies was estimated using the chi-square based Q-test \[[@pone.0225151.ref024]\], and quantified with the I^2^ statistic which measures degree of inconsistency between studies \[[@pone.0225151.ref025]\]. An I^2^ ≥ 50% with P ≤ 0.10 indicated the presence of heterogeneity, which prompted use of the random-effects model \[[@pone.0225151.ref026]\], otherwise the fixed- effects model was used \[[@pone.0225151.ref027]\]. Sources (outlying studies) of heterogeneity were detected with the Galbraith plot \[[@pone.0225151.ref028]\]. Outlier treatment consisted of eliminating sources of heterogeneity followed by reanalysis. Differential outcomes between the ethnicities (Asians, Caucasians or Africans) warranted tests of interaction \[[@pone.0225151.ref029]\]. Threshold for significance was set at P ≤ 0.05 (two-sided) except in estimations of heterogeneity \[[@pone.0225151.ref030]\]. Multiple comparisons were Bonferroni-corrected. Sensitivity analysis, which involves omitting one study at a time followed by recalculation, was used to test for robustness of the summary effects. Publication bias assessment was contingent on two conditions: i) statistically significant associations and ii) comparisons with ≥ 10 studies; less than this number reduces sensitivity of the qualitative and quantitative tests \[[@pone.0225151.ref031]\]. Distribution of continuous data was assessed with the Shapiro-Wilk (SW) test \[[@pone.0225151.ref032]\]. Normal distribution warranted the use of mean ± standard deviation (SD) and the parametric approach. Otherwise, non-normal data distribution was descriptively expressed as median and interquartile range (IQR), with an inferential non-parametric approach. Data were analyzed using Review Manager 5.3 (Cochrane Collaboration, Oxford, England), SIGMASTAT 2.03, SIGMAPLOT 11.0 (Systat Software, San Jose, CA).

Results {#sec012}
=======

Characteristics of the included studies {#sec013}
---------------------------------------

[Fig 1](#pone.0225151.g001){ref-type="fig"} outlines the study selection process in a flowchart following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines \[[@pone.0225151.ref033]\]. Initial search yielded a total of 325 citations; title and abstract screenings reduced this number to 51. Thirty four articles were excluded for not meeting our inclusion criteria; in addition, 4 articles/studies had absent or incomplete data ([S1 List](#pone.0225151.s001){ref-type="supplementary-material"}).

![Summary flowchart of literature search.](pone.0225151.g001){#pone.0225151.g001}

These series of exclusions resulted in 13 articles (studies) included in the meta-analysis \[[@pone.0225151.ref034]--[@pone.0225151.ref046]\]. Of the 13, three were included in the gene content analysis \[[@pone.0225151.ref035], [@pone.0225151.ref036], [@pone.0225151.ref039]\], five in the genotype analysis \[[@pone.0225151.ref034], [@pone.0225151.ref040]--[@pone.0225151.ref043]\] and five included both analyses \[[@pone.0225151.ref037], [@pone.0225151.ref038], [@pone.0225151.ref044]--[@pone.0225151.ref046]\]. [Table 1](#pone.0225151.t001){ref-type="table"} identifies which (Yes) articles cover gene content and genotype analyses. A total of 2,157 HIVI cases and 1,235 HESN controls were included in the meta-analysis ([S1](#pone.0225151.s002){ref-type="supplementary-material"} and [S2](#pone.0225151.s003){ref-type="supplementary-material"} Tables). S1 details the *KIR* polymorphisms for the gene content analysis and S2 outlines the *KIR3DL1/S1* genotypes (HIVI and HESN) for the genotype analysis. The number of articles included seven with Caucasian subjects (1,313 cases /485 controls)\[[@pone.0225151.ref040]--[@pone.0225151.ref044], [@pone.0225151.ref046], [@pone.0225151.ref047]\]; two Asians (256 cases /151 controls) \[[@pone.0225151.ref038], [@pone.0225151.ref039]\] and four Africans (588 cases /599 controls) \[[@pone.0225151.ref034]--[@pone.0225151.ref037]\]. Non-normal distribution of the CB scores (SW, P = 0.04) indicated high methodological quality of the included articles (median: 7, IQR: 6--8). [S1](#pone.0225151.s002){ref-type="supplementary-material"} and [S2](#pone.0225151.s003){ref-type="supplementary-material"} Tables show the quantitative traits of the included studies. Total sample sizes ranged from 41 to 577. Statistical power of the individual studies was low, but high at the aggregate level (99.9%) at α = 0.01 and OR of 1.5 (G\*Power program: <http://www.psycho.uni-duesseldorf.de/aap/>-projects/gpower). A detailed description of our study is summarized for PRISMA ([S3 Table](#pone.0225151.s004){ref-type="supplementary-material"}) and for genetic association studies ([S4 Table](#pone.0225151.s005){ref-type="supplementary-material"}).

10.1371/journal.pone.0225151.t001

###### Characteristics of the studies in the *KIR* polymorphisms and its associations with HIV acquisition.

![](pone.0225151.t001){#pone.0225151.t001g}

  K    First author   Year   Country        Ethnic Group   *KIR* gene content polymorphisms   *3DL1/S1* genotype polymorphisms   \[R\]
  ---- -------------- ------ -------------- -------------- ---------------------------------- ---------------------------------- ----------------------------
  1    Jennes         2006   Tanzania       African        No                                 Yes                                \[[@pone.0225151.ref034]\]
  2    Merino         2011   Zambia         African        Yes                                No                                 \[[@pone.0225151.ref035]\]
  3    Koehler        2013   Tanzania       African        Yes                                No                                 \[[@pone.0225151.ref036]\]
  4    Naranbhai      2016   South Africa   African        Yes                                Yes                                \[[@pone.0225151.ref037]\]
  5    Chavan         2014   India          Asian          Yes                                Yes                                \[[@pone.0225151.ref038]\]
  6    Mori           2015   Thailand       Asian          Yes                                No                                 \[[@pone.0225151.ref039]\]
  7    Boulet         2008   Canada         Caucasian      No                                 Yes                                \[[@pone.0225151.ref040]\]
  8    Guerin         2011   Italy          Caucasian      No                                 Yes                                \[[@pone.0225151.ref041]\]
  9    Habegger       2013   Argentina      Caucasian      No                                 Yes                                \[[@pone.0225151.ref042]\]
  10   Tallon         2014   Canada         Caucasian      No                                 Yes                                \[[@pone.0225151.ref043]\]
  11   Zwolinska      2016   Poland         Caucasian      Yes                                Yes                                \[[@pone.0225151.ref044]\]
  12   Jackson        2017   Canada         Caucasian      Yes                                Yes                                \[[@pone.0225151.ref045]\]
  13   Rallon         2017   Spain          Caucasian      Yes                                Yes                                \[[@pone.0225151.ref046]\]

K; number designation of each article, \[R\]; reference number

Overall comparisons {#sec014}
-------------------

### Gene content analysis {#sec015}

[Table 2](#pone.0225151.t002){ref-type="table"} shows eight significant outcomes, the P^a^ values of which ranged from high (\< 10^−5^) to marginal (0.05). Risks were increased in five and decreased in three outcomes. On account of two polymorphisms (*2DS4F* and *3DS1*), risks in the overall analysis were increased (OR 1.62, 95% CI 1.10, 2.37) and decreased (OR 0.76, 95% CI 0.57, 1.00), respectively. Subgroup-wise, Caucasians were susceptible on account of *2DL2* (OR 1.36, 95% CI 1.00, 1.84) and *2DS1* (OR 1.71, 95% CI 1.15, 2.53). Contrastingly, this subgroup was protected because of *2DL1* (OR 0.20, 95% CI 0.05, 0.79) and *2DL3* (OR 0.29, 95% CI 0.11, 0.75). Risks were increased for Asians (*2DL5B*: OR 2.80, 95% CI 1.17, 6.67) and Africans (*2DS4F*: OR 2.01, 95% CI 2.01, 3.18). Of note, only the *2DL3* polymorphism in Caucasians (OR 0.19, 95% CI 0.09, 0.40, P^a^ \< 10^−5^) survived the Bonferroni correction (P^c^ \< 10^−3^) which centralizes this finding for gene content analysis.

10.1371/journal.pone.0225151.t002

###### Associations of KIR gene content polymorphisms with HIV acquisition.

![](pone.0225151.t002){#pone.0225151.t002g}

  *KIR*                        Ethnicity      K   HIVI (n/N)    HESN (n/N)    Test of association   Test of heterogeneity   AM                                                                   
  ---------------------------- -------------- --- ------------- ------------- --------------------- ----------------------- --------------- ------------------- ------------------- ------- ---- ----
  ***Inhibitory KIR gene***                                                                                                                                                                      
  *2DL1*                       All            4   829/869       573/588       0.62                  0.32, 1.22              Decreased       0.17                \>1                 0.63    0    F
                               Caucasians     3   580/643       238/244       **0.20**              **0.05, 0.79**          **Decreased**   **0.02**            \>1                 0.11    54   F
                               Asians         2   243/256       139/151       1.20                  0.52, 2.74              Increased       0.67                \>1                 0.15    52   F
                               Africans       2   392/394       473/481       2.51                  0.47, 13.34             Increased       0.28                \>1                 0.28    15   F
  *2DL2*                       All            8   770/1,385     588/1,050     1.09                  0.91, 1.29              Increased       0.35                \>1                 0.48    0    F
                               Caucasians     3   354/643       115/244       **1.36**              **1.00, 1.84**          **Increased**   **0.05**            \>1                 0.38    0    F
                               Asians         2   115/256       80/151        0.88                  0.57, 1.36              Decreased       0.56                \>1                 1.00    0    F
                               Africans       3   301/486       393/655       1.00                  0.79, 1.29              Null            0.97                \>1                 0.55    0    F
  *2DL3*                       All            5   560/656       678/799       1.11                  0.82, 1.49              Increased       0.50                \>1                 0.76    0    F
                               Caucasians     3   518/643       226/244       **0.29**              **0.11, 0.75**          **Decreased**   **0.01**            0.70                0.06    65   R
                               Caucasians\*   2   409/520       137/147       **0.19**              **0.09, 0.40**          **Decreased**   **\< 10**^**−5**^   **\< 10**^**−3**^   0.46    0    F
                               Asians         2   238/256       128/151       2.02                  0.32, 12.96             Increased       0.46                \>1                 0.01    85   R
                               Africans       3   417/486       553/655       1.23                  0.88, 1.73              Increased       0.23                \>1                 0.97    0    F
  *2DL5A*                      All            3   194/718       111/478       0.73                  0.53, 1.01              Decreased       0.06                \>1                 0.92    0    F
                               Caucasian      1   147/431       42/105        0.78                  0.50, 1.20              Decreased       0.26                \>1                 NA      NA   NA
                               Africans       1   19/240        37/326        0.67                  0.38, 1.20              Decreased       0.18                \>1                 NA      NA   NA
  *2DL5B*                      All\*          3   268/718       228/478       1.14                  0.68, 1.91              Increased       0.62                \>1                 0.05    67   R
                               All            2   233/671       204/431       0.91                  0.69, 1.20              Decreased       0.51                \>1                 0.67    0    F
                               Asians         1   35/47         24/47         **2.80**              **1.17, 6.67**          **Increased**   **0.02**            \>1                 NA      NA   NA
                               Caucasians     1   108/431       30/105        0.84                  0.52, 1.35              Decreased       0.46                \>1                 NA      NA   NA
                               Africans       1   125/240       174/326       0.95                  0.68, 1.33              Decreased       0.76                \>1                 NA      NA   NA
  *3DL1*                       All            8   1,335/1,390   1,016/1,050   1.03                  0.64, 1.64              Null            0.91                \>1                 0.28    20   F
                               Caucasians     3   607/643       229/244       0.85                  0.29, 2.44              Decreased       0.76                \>1                 0.15    47   F
                               Asians         2   240/256       137/151       1.17                  0.54, 2.51              Increased       0.69                \>1                 0.20    38   F
                               Africans       3   488/491       650/655       0.95                  0.09, 9.87              Increased       0.97                \>1                 0.15    51   F
  ***Activating KIR genes***                                                                                                                                                                     
  *2DS1*                       All            6   260/834       211/758       0.95                  0.75, 1.20              Decreased       0.68                \>1                 0.48    0    F
                               Caucasians     3   267/643       88/244        1.27                  0.69, 2.33              Increased       0.44                \>1                 0.04    68   R
                               Caucasians\*   2   223/520       46/147        **1.71**              **1.15, 2.53**          **Increased**   **0.007**           0.49                0.90    0    F
                               Asians         2   120/256       79/151        0.90                  0.59, 1.35              Decreased       0.60                \>1                 0.84    0    F
                               Africans       2   64/394        79/481        1.04                  0.66, 1.63              Increased       0.88                \>1                 0.23    30   F
  *2DS2*                       All            6   428/834       386/758       1.08                  0.88, 1.32              Increased       0.48                \>1                 0.68    0    F
                               Caucasians     3   355/643       112/244       1.42                  0.97, 2.08              Increased       0.07                \>1                 0.25    28   F
                               Asians         2   120/256       75/151        1.27                  0.59, 2.75              Increased       0.55                \>1                 0.15    51   F
                               Africans       2   211/394       249/481       1.04                  0.80, 1.36              Increased       0.77                \>1                 0.87    0    F
  *2DS3*                       All            6   346/1,084     216/772       1.22                  0.87, 1.73              Increased       0.25                \>1                 0.06    53   R
                               All\*          4   168/564       186/625       0.97                  0.75, 1.25              Null            0.81                \>1                 0.48    0    F
                               Caucasians     3   213/643       59/244        1.53                  0.87, 2.17              Increased       0.14                \>1                 0.11    55   F
                               Africans       2   103/394       133/481       0.91                  0.67, 1.23              Decreased       0.53                \>1                 0.47    0    F
  *2DS4F*                      All            3   268/348       302/402       **1.62**              **1.10, 2.37**          **Increased**   **0.01**            0.70                0.15    47   F
                               Caucasians     3   243/643       75/244        1.47                  0.64, 3.41              Increased       0.37                \>1                 0.004   82   R
                               Caucasians\*   2   182/520       52/147        0.97                  0.66, 1.42              Null            0.87                \>1                 0.93    0    F
                               Africans       1   209/240       251/326       **2.01**              **2.01, 3.18**          **Increased**   **0.003**           0.21                NA      NA   NA
  *2DS4D*                      All            5   688/930       425/617       0.86                  0.67, 1.10              Decreased       0.24                \>1                 1.00    0    F
                               Caucasians     3   522/643       199/244       0.88                  0.59, 1.30              Decreased       0.51                \>1                 0.97    0    F
                               Africans       1   128/240       188/326       0.84                  0.60, 1.17              Decreased       0.30                \>1                 NA      NA   NA
  *2DS5*                       All            6   400/1,084     351/772       0.89                  0.73, 1.09              Decreased       0.27                \>1                 0.67    0    F
                               Caucasians     3   184/643       74/244        0.97                  0.65, 1.45              Null            0.89                \>1                 0.27    24   F
                               Africans       2   181/394       241/481       0.83                  0.64, 1.09              Decreased       0.19                \>1                 0.94    0    F
  *3DS1*                       All            5   186/773       172/729       **0.76**              **0.57, 1.00**          **Decreased**   **0.05**            \>1                 0.17    37   F
                               Caucasians     3   246/643       89/244        1.12                  0.71, 1.76              Increased       0.64                \>1                 0.17    44   F
                               Africans       3   41/491        55/655        1.19                  0.56, 2.56              Increased       0.65                \>1                 0.07    63   R
                               Africans\*     2   22/251        17/329        1.80                  0.93, 3.48              Increased       0.08                \>1                 0.65    0    F

K: number of studies; HIV: Human Immunodeficiency Virus; HIVI: HIV-Infected; HESN: *HIV-exposed seronegative*; n: number of individuals; N: total number; OR: odds ratio; CI: confidence interval; Null: OR 0.97--1.03; P^a^: P-value for test of association; P^c^: Bonferroni corrected P^a^; P^b^: P-value for heterogeneity; I^2^ is a measure of variability; Values in **bold** indicate significant associations; F: Fixed-effects; R: Random-effects; AM: Analysis Model; NA: Not applicable;\* outlier treated

### Genotype analysis of *3DL1/S1* {#sec016}

[Table 3](#pone.0225151.t003){ref-type="table"} shows three significant outcomes (P^a^ = 0.01--0.04) in PRO, none of which survived the Bonferroni-correction (P^c^ = 0.7 to \> 1) except *3DS1S1* in PSO (P^c^ \< 10^−3^) and this represents the core finding in our genotype analysis ([Table 4](#pone.0225151.t004){ref-type="table"}). Figs [2](#pone.0225151.g002){ref-type="fig"}--[4](#pone.0225151.g004){ref-type="fig"} summarize the mechanism of outlier treatment of this polymorphism. [Fig 2](#pone.0225151.g002){ref-type="fig"} shows in Caucasians, that the PRO reduced risk effect (OR 0.45, 95% CI 0.24, 0.84, P^a^ = 0.01) was heterogeneous (P^b^ \< 0.06, I^2^ = 50%). The source of this heterogeneity \[[@pone.0225151.ref044]\] is shown in [Fig 3](#pone.0225151.g003){ref-type="fig"}. [Fig 4](#pone.0225151.g004){ref-type="fig"} shows the PSO outcome (OR 0.37, 95% CI 0.24, 0.56, P^a^ *\<* 10^−5^) of intensified significance and reduced heterogeneity (P^b^ = 0.38, I^2^ = 5%).

![Pre-outlier (PRO) summary effects of *3DS1S1* on HIV acquisition in Caucasians.\
Diamond denotes the pooled odds ratio (OR) indicating reduced risk (OR 0.45). Squares show the OR of each study. Horizontal lines on either side of each square represent 95% confidence intervals (CIs). Significance from the Z test for overall effect is moderate (P^a^ = 0.01). The χ^2^ test shows the presence of heterogeneity (P^b^ = 0.06, I^2^ = 50%); I^2^: a measure of variability expressed in %.](pone.0225151.g002){#pone.0225151.g002}

![Galbraith plot analysis to detect the source of heterogeneity among Caucasian studies; the study above the +2 confidence limit is the outlier, Zwolinska et al \[[@pone.0225151.ref044]\]; whose presence in the PRO forest plot ([Fig 2](#pone.0225151.g002){ref-type="fig"}) accounts for 50% of the heterogeneity.\
Removal of this study \[[@pone.0225151.ref044]\] from the PSO forest plot ([Fig 4](#pone.0225151.g004){ref-type="fig"}) reduced the heterogeneity to 5%. OR: odds ratio; SE: standard error.](pone.0225151.g003){#pone.0225151.g003}

![Post-outlier (PSO) summary effects of *3DS1S1* on HIV acquisition in Caucasians.\
Diamond denotes the pooled odds ratio (OR) indicating reduced risk (OR 0.37). Squares show the OR of each study. Horizontal lines on either side of each square represent 95% confidence intervals (CIs). Significance from the Z test for overall effect is high (P^a^ \< 0.00001). The χ^2^ test shows reduced heterogeneity (P^b^ = 0.38, I^2^ = 5%); I^2^: a measure of variability expressed in %.](pone.0225151.g004){#pone.0225151.g004}

10.1371/journal.pone.0225151.t003

###### Summary associations of *3DL1/S1* genotypes and HIV acquisition in the pre-outlier (PRO) analysis.

![](pone.0225151.t003){#pone.0225151.t003g}

  *KIR* genotype   Comparisons   PRO   AM                                                                                                
  ---------------- ------------- ----- ------------- --------- ---------- ---------------- --------------- ---------- ------ ------ ---- ----
  *3DL1L1*         All           10    1,181/1,850   456/717   1.19       0.83, 1.71       Increased       0.34       \>1    0.01   60   R
                   Caucasians    7     1,010/1,629   286/494   1.20       0.81, 1.77       Increased       0.36       \>1    0.01   65   R
                   Asians        1     13/47         5/47      **3.21**   **1.04, 9.90**   **Increased**   **0.04**   \>1    NA     NA   NA
                   Africans      2     158/174       165/176   0.67       0.30, 1.49       Decreased       0.33       \>1    0.45   0    F
  *3DL1S1*         All           10    574/1,850     201/717   1.01       0.73, 1.41       Null            0.94       \>1    0.03   52   R
                   Caucasians    7     535/1,629     157/494   1.07       0.77, 1.47       Increased       0.70       \>1    0.09   45   R
                   Asians        1     24/47         35/47     **0.36**   **0.15, 0.85**   **Decreased**   **0.02**   \>1    NA     NA   NA
                   Africans      2     15/174        9/176     1.73       0.73, 4.09       Increased       0.21       \>1    0.52   0    F
  *3DS1S1*         All           8     94/1,850      58/717    0.54       0.29, 1.01       Decreased       0.06       \>1    0.02   59   R
                   Caucasians    7     84/1,629      51/494    **0.45**   **0.24, 0.84**   **Decreased**   **0.01**   0.70   0.06   50   R
                   Asians        1     10/47         7/47      1.54       0.53, 4.48       Increased       0.42       \>1    NA     NA   NA

PRO: pre-outlier; K: number of studies; HIV: Human Immunodeficiency Virus; HIVI: HIV-Infected; HESN: *HIV-exposed seronegative*; n: number of individuals; N: total number; OR: odds ratio; CI: confidence interval; Null: OR 0.97--1.03; P^a^: P-value for test of association; P^c^: Bonferroni corrected P^a^; P^b^: P-value for heterogeneity; I^2^ is a measure of variability; F: Fixed-effects; R: Random-effects; AM: Analysis Model; NA: Not applicable; Values in **bold** indicate significant associations.

10.1371/journal.pone.0225151.t004

###### Summary associations of *3DL1/S1* genotypes and HIV acquisition in the post-outlier (PSO) analysis.
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  *KIR* genotype   Ethnicity    K   HIVI (n/N)   HESN (n/N)   PSO        AM               Effects of outlier treatment                                                          
  ---------------- ------------ --- ------------ ------------ ---------- ---------------- ------------------------------ ------------------- ------------------- ------ --- --- --------
  *3DL1L1*         All          6   796/1,183    349/500      1.19       0.92, 1.53       Increased                      0.18                \>1                 0.47   0   F   EH, NC
                   Caucasians   4   638/1,009    184/324      1.27       0.98, 1.66       Increased                      0.08                \>1                 0.62   0   F   EH, NC
                   Africans     2   158/174      165/176      0.66       0.30, 1.46       Decreased                      0.30                \>1                 0.45   0   F   NC, NC
  *3DL1S1*         All          8   508/1,703    149/647      1.21       0.97, 1.51       Increased                      0.10                \>1                 0.8    0   F   EH, NC
                   Caucasians   6   493/1,529    140/471      1.17       0.93, 1.48       Increased                      0.18                \>1                 0.75   0   F   EH, NC
                   Africans     2   15/174       9/176        1.75       0.75, 4.12       Increased                      0.20                \>1                 0.52   0   F   NC, NC
  *3DS1S1*         Caucasians   6   62/1170      48/376       **0.37**   **0.24, 0.56**   **Decreased**                  **\< 10**^**−5**^   **\< 10**^**−3**^   0.38   5   F   RH, IS

PSO: post-outlier; K: number of studies; HIV: Human Immunodeficiency Virus; HIVI: HIV-Infected; HESN: *HIV-exposed seronegative*; n: number of individuals; N: total number; OR: odds ratio; CI: confidence interval; P^a^: P-value for test of association; P^c^: Bonferroni correction for P^a^; P^b^: P-value for heterogeneity; I^2^ is a measure of variability; F: Fixed-effects; AM: Analysis Model; EH: eliminated heterogeneity; RH: reduced heterogeneity; IS: intensified significance; NC: no change; Values in **bold** indicate significant associations

### Tests of interaction {#sec017}

[S5 Table](#pone.0225151.s006){ref-type="supplementary-material"} shows that of the 10 comparisons subjected to these tests, only the Caucasian effect in *2DL3* (OR 0.19, P^a^ \< 10^−5^) compared with that of the African effect (OR 1.23, P^a^ = 0.23) resulted in significant interaction (P^ci^ \< 10^−4^) suggesting improved association. Extent of the significant Caucasian effect is thus placed in context when compared with its non-significant African counterpart.

### Sensitivity analysis {#sec018}

[Table 5](#pone.0225151.t005){ref-type="table"} shows all significant outcomes in the overall and subgroup analyses were unaffected by sensitivity treatment except the *2DL2*, *2DS1* and *3DS1* (gene content analysis) and *3DL1/S1* in PRO Caucasians (genotype analysis).

10.1371/journal.pone.0225151.t005

###### Sensitivity analysis outcomes.
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  ------------------------- ------------ ---------------------------------------------------------------------------- --------
  ***KIR* genes content**                                                                                             
  polymorphism              Population   Genetic effects                                                              
  *2DL1*                    Caucasians   Robust                                                                       
  *2DL2*                    Caucasians   \[[@pone.0225151.ref044], [@pone.0225151.ref046]\]                           
  *2DL3*                    Caucasians   Robust                                                                       
  *2DS1*                    Caucasians   \[[@pone.0225151.ref044]\]                                                   
  *2DS4F*                   All          Robust                                                                       
  *3DS1*                    All          \[[@pone.0225151.ref035], [@pone.0225151.ref038], [@pone.0225151.ref045]\]   
  ***3DL1/S1* genotype**                                                                                              
  polymorphism                           PRO                                                                          PSO
  *3DS1S1*                  All          None                                                                         Robust
  *3DS1S1*                  Caucasians   \[[@pone.0225151.ref040], [@pone.0225151.ref041], [@pone.0225151.ref045]\]   Robust
  ------------------------- ------------ ---------------------------------------------------------------------------- --------

PRO: pre--outlier; PSO: post-outlier; the value in brackets indicate the reference articles that contributed to instability of associations.

### Publication bias {#sec019}

Two outcomes (*3DL1L1* and *3DS1S1*) in our meta-analysis had 10 studies which we subjected to the funnel plot analysis and tests for publication bias. Operating data (ORs) for *3DL1L1* and *3DS1S1* were respectively non-normal (SW: P \< 0.001) and normal (SW: P = 0.053). Neither the *3DL1L1* (Begg Mazumdar: Kendall\'s tau = 0.07, P = 0.79) and *3DS1S1* (Egger's test: intercept: -0.40, P = 0.77) outcomes nor the funnel plot show evidence of publication bias ([Fig 5](#pone.0225151.g005){ref-type="fig"}).

![Funnel plot analysis of *3DL1/S1* genotype for publication bias.\
OR: odds ratio; SE: standard error.](pone.0225151.g005){#pone.0225151.g005}

Discussion {#sec020}
==========

Summary of findings {#sec021}
-------------------

Lack of evidence (mainly low number of studies) precluded conclusions about Asians and Africans. Our main findings are thus confined to Caucasians, who are afforded protection by two *KIR* polymorphisms (*2DL3* and *3DS1S1*) on account of a number of meta-analysis treatments. Between the two polymorphisms, *2DL3* presents strong evidence on account of the magnitude of protective effect (81%), associative and interaction outcomes (P^ci^ \< 10^−4^). On the other hand, *3DS1S1* is strong based on number of studies and aggregate statistical power ([Table 6](#pone.0225151.t006){ref-type="table"}). The advantage or disadvantages of using sensitivity approach versus eliminating the outlier is contextualized in terms of the following: Sensitivity treatment evaluates robustness of the pooled ORs while outlier elimination addresses heterogeneity. Favorable outcome of sensitivity analysis is robustness, where no study contributed to instability of the results. On the other hand, favorable outcomes of outlier treatment involve both heterogeneity and significance. In our study, heterogeneity was either reduced or eliminated; significance was intensified. These effects from outlier treatment and those from sensitivity analysis, contribute to strengthening the evidence that we present.

10.1371/journal.pone.0225151.t006

###### Comparative summary effects between *2DL3* and *3DS1S1* on HIV acquisition in Caucasians in PSO.
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  Parameter                           *2DL3*       *3DS1S1*
  ----------------------------------- ------------ ------------
  N                                   2            6
  n                                   677          1,546
  Aggregate statistical power         57%          92%
  OR                                  0.19         0.37
  Magnitude of protective effect      81%          63%
  95% CI                              0.09, 0.40   0.24, 0.56
  CI difference (upper CI-lower CI)   0.31         0.32
  Direction of risk effects           Decreased    Decreased
  P^c^                                \< 10^−3^    \< 10^−3^
  P^ci^                               \< 10^−4^    0.14
  Sensitivity analysis outcomes       Robust       Robust

PSO: post-outlier; N: number of included studies; n: sample size; P^c^: Bonferroni-corrected P-value; P^ci^: Bonferroni-corrected P-value for interaction; OR: odd ratio; CI: confidence interval

Functional correlates {#sec022}
---------------------

Between our two main findings, *3DS1S1* appears to have stronger support from functional studies than *2DL3*. Because *3DS1* is more prominent in the HIV literature \[[@pone.0225151.ref048]\] than *2DL3*, functional correlate narrative here refer to *3DS1*. In the proposed model explaining results based on the concept of "NK licensing", individuals carrying *3DS1* would lead to stronger NK cell activation by degranulation and cytokine release to control early HIV-1 infection \[[@pone.0225151.ref049], [@pone.0225151.ref050]\]. Essentially, functional studies support the protective effect of *3DS1* \[[@pone.0225151.ref051]--[@pone.0225151.ref053]\]. An increase IFN-γ and CD107a expressions of NK cells were observed in *3DS1* individuals with early HIV-1 infection \[[@pone.0225151.ref052]\].

The roles of 3DS1^+^NK cells in HIV infection are two-fold, one, is expansion in acute HIVI individuals \[[@pone.0225151.ref015]\] and the other is increased antiviral activity in HIV-infected cells \[[@pone.0225151.ref049]\]. The nature of *KIR* influence on HIV-infection is admittedly more complex than the sum of the meta-analytical evidence and functional support for our findings. The complexity is made more elaborate from three viewpoints: (i) *in vivo*/*in vitro* effects of *KIR* on HIVI; (ii) extensive genetic diversity of *KIR* among populations; and (iii) influence of linkage disequilibrium, raising the possibility that the observed effect maybe mediated by *3DS1* or other *KIRs*.

*KIR* polymorphisms in meta-analysis {#sec023}
------------------------------------

To our knowledge, this is the first meta-analysis that examines *KIR* effects on HIV acquisition. By extension, associations of the *KIR* polymorphisms have been reported in a number of meta-analyses that included disease endpoints such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus and multiple sclerosis \[[@pone.0225151.ref054]--[@pone.0225151.ref057]\]. The only other meta-analysis for *KIR* polymorphisms with another infectious disease is that of Gauthiez et al's examination of the Hepatitis C Virus (HCV) infection with HCV clearance \[[@pone.0225151.ref058]\]. Owing to the incompatibility of results, we compare the two meta-analyses based on methodology. [S6 Table](#pone.0225151.s007){ref-type="supplementary-material"} summarizes the comparative features of the two meta-analyses. In common between the two studies are the uses of I^2^ to evaluate heterogeneity and Mantel-Haenszel and DerSimonian-Laird for fixed and random-effects, respectively. Meta-analysis features covered in this study but not in Gauthiez et al \[[@pone.0225151.ref058]\] were assessment of study quality, interaction test, outlier treatment and correction for multiplicity.

*KIR* and GWAS {#sec024}
--------------

Genome-wide association studies (GWAS) is a powerful approach to unravel the genetics behind complex diseases \[[@pone.0225151.ref059]\]. In HIV research, GWAS has identified a number of SNPs associated with different forms of HIV progression \[[@pone.0225151.ref060]\]. The first GWAS in the HIV context was in the HLA class I locus that confirmed a major effect of *HLA-B\*57* in reducing viral load \[[@pone.0225151.ref061]\]. Containment of viral load in the early stages of HIV infection is facilitated by the HLA-B/KIR genotype which enhances activation of NK cells \[[@pone.0225151.ref062]\]. Evidence for KIR-HLA suggests complex interactions but GWAS appears to be problematic in examining the role of this locus in the genome context \[[@pone.0225151.ref063]\]. The reason for this problematic approach relates to the following: One, HLA-KIR molecules are encoded by two of the most diverse gene families in the human genome \[[@pone.0225151.ref064]\]. Diversity of the HLA and KIR loci impacts viral pathogenesis differentially across individuals \[[@pone.0225151.ref064]\]. Two, the *KIR* locus contains variations of the KIR genes. This variation is functionally relevant only in the presence of alleles encoding their specific HLA ligands \[[@pone.0225151.ref063]\]. For example, disabled protectivity of the HLA-B allele without *3DS1* contrasts with *3DS1*-related AIDS progression in the absence of specific HLA-B alleles \[[@pone.0225151.ref065]\]. Thus, variation in the genes encoding KIR proteins, particularly *3DL1* and *3DS1*, has been associated with HIV-1 outcomes in many genetic and functional studies \[[@pone.0225151.ref066]\], but these have not been identified by GWAS, almost certainly because of the extreme inter- and intragenic variability of the *KIR* haplotypes \[[@pone.0225151.ref067]\]. Three, on the fundamental level, the agnostic approach of GWAS in analyzing SNPs limits the assessment of functionally dependent variants such as that shown by HLA-KIR \[[@pone.0225151.ref063]\].

Strengths and limitations {#sec025}
-------------------------

Our results are better contextualized with awareness of their strengths and limitations. The strengths include: (i) impact of outlier treatment on associative significance and heterogeneity; (ii) added evidence of the high methodological quality of all 13 articles with CBS scores of ≥ 5; (iii) of the 70 comparisons, 53 (81%) were non-heterogeneous (fixed-effects); of the 53, 31 (58%) had zero heterogeneity (I^2^ = 0%); (v) one core finding (*3DS1S1*) in the genotype analysis had high statistical power (92%); (vi) sensitivity treatment confirmed robustness of our core findings. On the other hand, limitations comprise of the following: (i) effects of gene-gene and gene-environment interactions were not addressed due to the lack of adequate data; (ii) few studies for Africans and Asians resulted in under-representation of these ethnic groups; (iii) the linkage disequilibrium effect may involve other proximal *KIR* polymorphisms that might account for the associations; (iv) 10 comparisons had only one study (four Asians, four Africans and two Caucasians) and (v) one core finding (*2DL3*) in the gene content analysis were statistically underpowered (57%).

Conclusion {#sec026}
==========

This study hopes to contribute to the genetic knowledge of this epidemiologically important infectious disease. Although our findings are admittedly modest, they profile the role of the two polymorphisms (*2DL3* and *3DS1S1*) in HIV acquisition. Considered individually, other *KIR* polymorphisms may have influence and would probably require analyses of haplotypes and HLA ligands to distinguish combined effects. These approaches may elaborate on how genetic variation cooperates in NK-mediated protection against HIV infection. Such analyses may shed light on the complexities of *KIR*'s involvement in the innate immune responses of HIV acquisition.
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======================

###### Excluded studies after abstract screening and full-text articles assessed for eligibility.

(DOCX)

###### 

Click here for additional data file.

###### Characteristics of the studies in the *KIR* gene content polymorphisms and its associations with HIV acquisition.

(DOCX)

###### 

Click here for additional data file.

###### Characteristics of the studies in the *3DL1/S1* genotype polymorphisms and its associations with HIV acquisition.

(DOCX)

###### 

Click here for additional data file.

###### PRISMA checklist.

(DOCX)

###### 

Click here for additional data file.

###### Genetic association checklist.

(DOCX)

###### 

Click here for additional data file.

###### Tests of interaction.

(DOCX)

###### 

Click here for additional data file.

###### Comparison of two meta-analyses based on methodology.

(DOCX)

###### 

Click here for additional data file.

SC was supported by Thailand Research Fund and the Commission on Higher Education under the Grant for New Researcher (No.MRG 6180172).

\[R\]

:   Reference number

CB

:   Clark-Baudouin

CI

:   Confidence interval

HESN

:   Human Immunodeficiency Virus-exposed seronegative

HIV

:   Human Immunodeficiency Virus

HIVI

:   HIV-infected

HLA

:   Human Leukocyte Antigen

I^2^

:   Heterogeneity test

IQR

:   Interquartile range

K

:   Number of studies

KIR

:   Killer Immunoglobulin-like receptor

maf

:   minor allele frequency

n

:   Sample size or number of individuals

N

:   Total number of studies

NK

:   Natural Killer cells

OR

:   Odds ratio

P^a^

:   P-value for test of association (pre-Bonferroni

P^b^

:   P-value for test of heterogeneity

P^c^

:   Bonferroni-corrected P-value for association

P^ci^

:   Bonferroni-corrected P-value for interaction

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PRO

:   Pre-outlier

PSO

:   Post-outlier

SD

:   Standard deviation

10.1371/journal.pone.0225151.r001

Author response to previous submission

26 Jun 2019

###### 

Submitted filename: Responses to editorial comments 26 June 2019.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0225151.r002

Decision Letter 0

Mummidi

Srinivas

Academic Editor

© 2019 Srinivas Mummidi

2019

Srinivas Mummidi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

7 Aug 2019

PONE-D-19-15826

Effects of the killer immunoglobulin--like receptor (KIR) polymorphisms on HIV acquisition: a meta-analysis

PLOS ONE

Dear Dr. Pabalan,

Thank you for submitting your manuscript to PLOS ONE. Both reviewers felt that the study was well designed and executed. There are some minor concerns that were expressed which could be easily addressed.​

We would appreciate receiving your revised manuscript by 10/1/2019. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Srinivas Mummidi, D.V.M., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.  Thank you for stating in your Funding Statement:

 \[SC was supported by Thailand Research Fund and the Commission on Higher Education under the Grant for New Researcher (No.MRG 6180172)\]. 

\* Please provide an amended statement that declares \*all\* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>.  Please also include the statement "There was no additional external funding received for this study." in your updated Funding Statement.

\* Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have done a terrific job at reviewing the relevant literature on the role of KIR polymorphisms in HIV acquisition, and, more importantly, at extracting the data and meta-data from these studies to perform a meta-analysis. The meta-analysis was satisfactorily performed. Scoring and ranking studies according to the CB scale lends credence to the meta-analysis to the extent that it establishes the quality of the \"input\" studies.

A major finding of the study is that the 2DL3 polymorphism is significantly protective against HIV acquisition even after Bonferroni correction. This was established only after outlier removal where outlier studies were identified by heterogeneity analysis and removed accordingly. The subsequent post-outlier treatment analysis yielded a strong inference that 2DL3 is indeed protective against HIV acquisition.

There are two very minor suggestions that may strengthen the paper a little bit:

1\) Clarification and interpretation of the significant interaction result between Caucasians and Africans. What does this mean even simply at an epidemiological level?

2\) The Benjamini-Hochberg false discovery rate (BH FDR) is often a desirable alternative to the more rigorous Bonferroni correction in that it represents a nice balance between guarding against false discoveries and making true discoveries, as opposed to simply guarding against false discoveries in a relatively more conservative manner (as in the Bonferroni correction). This is not necessary for the authors to implement but its implementation may yield more results surviving multiple correction if the BH FDR is used.

Reviewer \#2: This is an interesting meta-analysis for effects of genetic variants on HIV acquisition.

The paper was well written and methods were rigorously used and described. A minor comment regarding the Galbraith plot. Was it based on an specific protective size of effect? Please define in the text if you did so. It is advisable to the authors include the size of effect plot (arc) on Figure 3. Define Zwoliska in the same figure legend. This unique point was responsible for the 45% heterogeneity between studies. There was not mention on the discussion regarding the advantage or disadvantages of using sensitivity approach versus eliminating the outlier.

Table 4 should clarify if the numbers in brackets are those affecting the results? (i.e.: Modifying the ORs in extreme results?). Can you clarify their significance?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0225151.r003

Author response to Decision Letter 0

31 Aug 2019

Reviewer \#1: The authors have done a terrific job at reviewing the relevant literature on the role of KIR polymorphisms in HIV acquisition, and, more importantly, at extracting the data and meta-data from these studies to perform a meta-analysis. The meta-analysis was satisfactorily performed. Scoring and ranking studies according to the CB scale lends credence to the meta-analysis to the extent that it establishes the quality of the \"input\" studies.

A major finding of the study is that the 2DL3 polymorphism is significantly protective against HIV acquisition even after Bonferroni correction. This was established only after outlier removal where outlier studies were identified by heterogeneity analysis and removed accordingly. The subsequent post-outlier treatment analysis yielded a strong inference that 2DL3 is indeed protective against HIV acquisition.

There are two very minor suggestions that may strengthen the paper a little bit:

COMMENT:

1\) Clarification and interpretation of the significant interaction result between Caucasians and Africans. What does this mean even simply at an epidemiological level?

RESPONSE:

We clarify and interpret the significant interaction result between Caucasians and Africans. Prevalence of HIV in Africa is higher compared to that in North America and Europe (Caucasians) \[1\]. This epidemiological finding suggests less risk for Caucasians and higher risk for Africans which agrees with our 2DL3 result that protects Caucasians (OR, 0.19) from risk of HIV acquisition.

LINES 306-308

Extent of the significant Caucasian effect is thus placed in context when compared with its non-significant African counterpart.

COMMENT:

2\) The Benjamini-Hochberg false discovery rate (BH FDR) is often a desirable alternative to the more rigorous Bonferroni correction in that it represents a nice balance between guarding against false discoveries and making true discoveries, as opposed to simply guarding against false discoveries in a relatively more conservative manner (as in the Bonferroni correction). This is not necessary for the authors to implement but its implementation may yield more results surviving multiple correction if the BH FDR is used.

RESPONSE:

We sincerely thank the reviewer for the insight provided about correcting for multiple comparisons. We did implement BH-FDR and obtained 11 significant P-values against the two with the Bonferroni correction. Then we found that explaining the 11 significant outcomes did not readily converge with the epidemiology and physiology literature. From the BH-FDR approach, this made the explanations messy which muddled the principal message of our study. Thus, we found that applying the Bonferroni correction, conservative as it is, readily lent more credence to our main message with better support from the literature.

\*The Table at the end of this document puts the BH-FDR results in column

Reviewer \#2: This is an interesting meta-analysis for effects of genetic variants on HIV acquisition.

The paper was well written and methods were rigorously used and described.

COMMENT:

A minor comment regarding the Galbraith plot. Was it based on an specific protective size of effect?

RESPONSE:

We thank the reviewer for this question. The Galbraith plot is mainly used to find source(s) of heterogeneity in meta-analysis. Thus, it would identify which component study/studies are outliers. In calculating the values along the Y-axis (log OR / SE), we indeed use the range of effect sizes (which maybe from protective to increased risk) from all the included studies in order to derive the log values. Rather than the specific protective size of effect as basis, it is the consequence of outlier analysis, which the Galbraith plot is the main instrument in identifying the outlier(s).

COMMENT:

Please define in the text if you did so. It is advisable to the authors include the size of effect plot (arc) on Figure 3.

RESPONSE:

The reason we use the log OR /SE is to derive positive and negative confidence limits for the Galbraith plot along the y-axis. Unfortunately, size of effect plot (arc) did not allow the above when we attempted to do so.

COMMENT:

Define Zwoliska in the same figure legend. This unique point was responsible for the 45% heterogeneity between studies.

RESPONSE: In the legend of figure 3 (below) we define the role of the outlying study, Zwolinska et al in terms of the heterogeneity in the Caucasian forest plot of the 3DS1S1 genotype comparison.

LINES 621-625

Figure 3: Galbraith plot analysis to detect the source of heterogeneity among Caucasian studies; the study above the +2 confidence limit is the outlier, Zwolinska et al \[44\]; whose presence in the PRO forest plot (Figure 2) accounts for 50% of the heterogeneity. Removal of this study \[44\] from the PSO forest plot (Figure 4) reduced the heterogeneity to 5%. OR: odds ratio; SE: standard error.

COMMENT:

There was not mention on the discussion regarding the advantage or disadvantages of using sensitivity approach versus eliminating the outlier.

RESPONSE: We thank the reviewer for this comment. We explain the pros and cons of using sensitivity analysis in the Discussion. Mainly, pooled ORs need to be tested for their stability. We address the question: will any study-specific OR be responsible for the instability of the pooled OR? This is tested simply by omitting one study at a time then recalculating the pooled OR without that study.

LINES 356-363

The advantage or disadvantages of using sensitivity approach versus eliminating the outlier is contextualized in terms of the following: Sensitivity treatment evaluates robustness of the pooled ORs while outlier elimination addresses heterogeneity. Favorable outcome of sensitivity analysis is robustness, where no study contributed to instability of the results. On the other hand, favorable outcomes of outlier treatment involve both heterogeneity and significance. In our study, heterogeneity was either reduced or eliminated; significance was intensified. These effects from outlier treatment and those from sensitivity analysis, contribute to strengthening the evidence that we present.
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Table 4 should clarify if the numbers in brackets are those affecting the results? (i.e.: Modifying the ORs in extreme results?). Can you clarify their significance?
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LINES 336-337

PRO: pre--outlier; PSO: post-outlier; the value in brackets indicate the references articles that contributed to instability of associations.
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